Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

Figure 6

The S2-Ag85A oral vaccine provides better protection against Brucella infection in mice. (a) The bacterial content in the spleen of rats in each group was roughly the same one week after infection, and the bacterial content showed a significantly lower level in the spleen of mice in the S2 and S2-Ag85A groups than that in the model group at the 5th week (). (b) At each of 1-5 weeks, the weight of the spleen of mice in the group showed an upward trend. After 5 weeks, the spleen began to atrophy, and the weight of the spleen began to decrease. The mice in the 5, 9, and 11 W S2-Ag85A groups showed a significantly elevated weight of spleen than that in the model group ( value < 0.05). (c) From the first week, in the beginning, the S2 group, Ag85A group, and model group showed different degrees of death, and these group showed a significantly elevated death rate than that in the S2-Ag85A group ( value < 0.05).

(a)

(b)

(c)